Astrazeneca gets personal
A collaboration this week with the blood testing specialist Capitainer underlines the big pharma’s ambition to have a diagnostic linked with every pipeline project.
Biotech tries everything it can in Nash
The Nash pipeline is pharmacologically diverse, and some projects look like very long shots.
Madrigal changes the tune in Nash
A smash hit in resmetirom’s pivotal trial sets up an accelerated approval filing next year.
Lilly and Pfizer fight for new territory in obesity and diabetes
Both developers lay out ambitious plans for oral projects to rival injected GLP-1s, while Lilly strives to build on Mounjaro.
Amgen tries something new in obesity
Early data are promising, but the upcoming phase 2 trial has questions to answer.
Boston’s struggle with obesity
With an effective obesity drug already available and more in the pipeline, what hope do devices have?
AHA 2022 – Amgen looks good in metabolic disease
With a mid-stage win in cholesterol lowering in the bag, attention turns to obesity.
